

Patent Application
Attorney Docket NO. PC11724H US

AMENDMENTS TO THE CLAIMS

1- 86. (CANCELED)

87. (CURRENTLY AMENDED) An azithromycin mixture comprising substantially pure azithromycin monohydrate hemi-ethanol solvate characterized as having a plurality of ^{13}C solid state NMR peaks with at least two peaks at approximately 179.5 ± 0.2 ppm and 178.6 ± 0.2 ppm and optionally less than 10% by weight of azithromycin dihydrate characterized as having at least three ^{13}C solid state NMR peaks at approximately 13.2ppm, 11.3ppm and 7.2 ppm; wherein said substantially pure azithromycin monohydrate hemi-ethanol solvate contains less than 10% of alternative polymorphic or isomorphic crystalline forms of azithromycin by weight.

88 - 125. (CANCELED)

126. (CURRENTLY AMENDED) The azithromycin mixture of claim 87, wherein said ^{13}C solid state NMR spectrum further comprises a peak with chemical shift of about 58.0 ppm.
127. (PREVIOUSLY PRESENTED) The azithromycin mixture of claim 126, wherein said ^{13}C solid state NMR spectrum further comprises a peak with chemical shift of about 17.2 ppm.
128. (PREVIOUSLY PRESENTED) The azithromycin mixture of claim 127, wherein said ^{13}C solid state NMR spectrum further comprises a peak with chemical shift of about 10.1 ppm.
129. (PREVIOUSLY PRESENTED) The azithromycin mixture of claim 128, wherein said ^{13}C solid state NMR spectrum further comprises a peak with chemical shift of about 9.8 ppm.
130. (PREVIOUSLY PRESENTED) The azithromycin mixture of claim 129, wherein said ^{13}C solid state NMR spectrum further comprises a peak with chemical shift of about 9.3 ppm.

Patent Application
Attorney Docket NO. PC11724H US

131. (PREVIOUSLY PRESENTED) The azithromycin mixture of claim 130, wherein said ^{13}C solid state NMR spectrum further comprises a peak with chemical shift of about 7.9 ppm.
132. (PREVIOUSLY PRESENTED) The azithromycin mixture of claim 131, wherein said ^{13}C solid state NMR spectrum further comprises a peak with chemical shift of about 6.6 ppm.
133. (NEW) The azithromycin mixture of claim 87 wherein said substantially pure azithromycin monohydrate hemi-ethanol solvate contains less than 5% of alternative polymorphic or isomorphic crystalline forms of azithromycin by weight.
134. (NEW) The azithromycin mixture of claim 87 wherein said substantially pure azithromycin monohydrate hemi-ethanol solvate contains less than 1% of alternative polymorphic or isomorphic crystalline forms of azithromycin by weight.
135. (NEW) The azithromycin mixture of claim 87 wherein said azithromycin mixture optionally contains less than 5% of azithromycin dihydrate by weight.
136. (NEW) The azithromycin mixture of claim 87 wherein said azithromycin mixture optionally contains less than 1% of azithromycin dihydrate by weight.